Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: Gradient of benefit related to the revascularization strategy.
European Heart Journal.
Times cited: 131
One-year survival following early revascularization for cardiogenic shock.
JAMA - Journal of the American Medical Association.
Times cited: 471
Roundtable panel discussion: The role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes.
American Journal of Cardiology.
Times cited: 2